Is MYOV or DGRO a better dividend investment in 2026?

MYOV currently yields 7.41% with a 5% 5-year dividend growth rate. DGRO yields 2.10% with 9.5% growth. The better choice depends on your goal: MYOV offers higher current income.

What is the dividend yield difference between MYOV and DGRO?

MYOV has a forward dividend yield of 7.41% ($2.00/share annually). DGRO yields 2.10% ($1.47/share annually). The yield gap is 5.31 percentage points.

Home › Compare › MYOV vs DGRO

MYOV vs DGRO: Dividend Comparison 2026

MYOV yields 7.41% · DGRO yields 2.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MYOV wins by $1.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MYOV

● Live price

7.41%

Share price

$26.98

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$32.7K

Annual income

$1,186.18

Full MYOV calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.10%

Share price

$70.18

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$235.38

Full DGRO calculator →

Portfolio growth — MYOV vs DGRO

📍 MYOV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MYOV	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MYOV + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MYOV pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV

Annual income on $10K today (after 15% tax)

$630.10/yr

After 10yr DRIP, annual income (after tax)

$1,008.25/yr

DGRO

Annual income on $10K today (after 15% tax)

$178.14/yr

After 10yr DRIP, annual income (after tax)

$200.07/yr

At 15% tax rate, MYOV beats the other by $808.18/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + DGRO for your $10,000?

MYOV: 50%DGRO: 50%

100% DGRO50/50100% MYOV

Portfolio after 10yr

$32.1K

Annual income

$710.78/yr

Blended yield

2.21%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MYOV right now

MYOV

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-3.0

Piotroski

2/9

DGRO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys

DGRO buys

No recent congressional trades found for MYOV or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMYOVDGRO

Forward yield	7.41% ✓	2.10%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$32.7K ✓	$31.6K
Annual income after 10y	$1,186.18 ✓	$235.38
Total dividends collected	$9.7K ✓	$2.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MYOV vs DGRO ($10,000, DRIP)

Year	MYOV Portfolio	MYOV Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$11,441	$741.29	$11,290	$209.57	+$151.00 → MYOV
2	$13,035	$792.65	$12,722	$213.54	+$313.00 → MYOV
3	$14,791	$843.97	$14,314	$217.18	+$477.00 → MYOV
4	$16,722	$895.04	$16,080	$220.53	+$642.00 → MYOV
5	$18,838	$945.65	$18,040	$223.59	+$798.00 → MYOV
6	$21,152	$995.63	$20,215	$226.40	+$937.00 → MYOV
7	$23,678	$1,044.81	$22,627	$228.96	+$1.1K → MYOV
8	$26,428	$1,093.05	$25,302	$231.31	+$1.1K → MYOV
9	$29,418	$1,140.20	$28,268	$233.44	+$1.1K → MYOV
10	$32,664	$1,186.18	$31,557	$235.38	+$1.1K → MYOV

MYOV vs DGRO: Complete Analysis 2026

MYOV — Stock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this MYOV vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHD MYOV vs JEPI MYOV vs O MYOV vs KO MYOV vs MAIN MYOV vs VIG MYOV vs NOBL MYOV vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.